BAL PHARMA LTD.
BALPHARMA · General/Diversified · NSE
₹77
Current Market Price
Fair Value (DCF)
₹37
Margin of Safety
-52.5%
Updated 14h ago
YieldIQ Score
33/100
Piotroski F-Score
4/9
Economic Moat
Narrow
Confidence
15%
ROE
—
Debt/Equity
1.98
WACC
11.1%
Market Cap
₹123 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
16.9%
Return on capital employed
EV / EBITDA
11.2×
Enterprise multiple
Debt / EBITDA
6.2×
Leverage vs earnings
Interest Coverage
1.4×
EBIT covers interest
Current Ratio
1.07×
Short-term liquidity
Asset Turnover
0.90×
Revenue per ₹ of assets
Revenue CAGR (3Y)
2.7%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹77.18
Bear case
₹32.71
MoS -136.0%
Base case
₹36.64
MoS -110.6%
Bull case
₹71.64
MoS -7.7%
Ratio Trends
BALPHARMA · last 4 annual periods
ROE
9.3%
ROCE
12.9%
Operating Margin
—
Debt / Equity
1.94×
PE
41.5×
EV / EBITDA
9.8×
Historical Financials
BALPHARMA · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹280 Cr | ₹302 Cr | ₹339 Cr | ₹303 Cr | +2.7% |
| EBITDA | ₹27.1 Cr | ₹24.4 Cr | ₹33.6 Cr | ₹29.4 Cr | +2.8% |
| EBIT | — | — | — | — | — |
| PAT | ₹5.6 Cr | ₹2.6 Cr | ₹7.4 Cr | ₹7.2 Cr | +8.7% |
| EPS (diluted) | — | — | — | — | — |
| CFO | ₹26.8 Cr | ₹-1.5 Cr | ₹22.8 Cr | ₹20.3 Cr | -8.8% |
| CapEx | ₹-8.5 Cr | ₹-14.6 Cr | ₹-11.0 Cr | ₹-18.8 Cr | — |
| FCF | ₹18.3 Cr | ₹-16.2 Cr | ₹11.8 Cr | ₹1.5 Cr | -56.3% |
| Total Assets | ₹261 Cr | ₹313 Cr | ₹320 Cr | ₹336 Cr | +8.8% |
| Total Debt | ₹107 Cr | ₹133 Cr | ₹142 Cr | ₹150 Cr | +12.1% |
| Shareholders' Equity | ₹58.5 Cr | ₹63.7 Cr | ₹72.0 Cr | ₹77.4 Cr | +9.8% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
BALPHARMA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| PAR PAR | — | — | Pending | 13.5% | — |
| KREBSBIO KREBSBIO | — | — | Pending | 18.4% | — |
| ALPA ALPA | — | — | Pending | 11.4% | — |
| VAISHALI VAISHALI | — | — | Pending | 1.3% | — |
| NATCAPSUQ NATCAPSUQ | — | — | Pending | 0.2% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for BALPHARMA in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of BALPHARMA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for BALPHARMA →
Compare
Head-to-head with peers
Compare BALPHARMA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse BALPHARMANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.